Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Single Arm, Phase 2, Open-Label Study to Determine the Efficacy of Twice Daily Oral Dosing of PKC412 <Midostaurin> Administered to Patients With Aggressive Systemic Mastocytosis (ASM) and Mast Cell Leukemia (MCL)

NCT00233454 is registered in ClinicalTrials.gov with Jason Robert Gotlib as lead sponsor.

NCT NCT00233454
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00233454 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Single Arm, Phase 2, Open-Label Study to Determine the Efficacy of Twice Daily Oral Dosing of PKC412 <Midostaurin> Administered to Patients With Aggressive Systemic Mastocytosis (ASM) and Mast Cell Leukemia (MCL)
Lead sponsor
Jason Robert Gotlib
Phase
Phase 2
Overall status
Completed
Start date
March 31, 2005
Completion date
April 16, 2011
Enrollment
26 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

hematological non-mast cell lineage disease (ahnmd), leukemia, mast cell, systemic mastocytosis, aggressive (asm)